The very first patient treated with CTX001 is now at a 15-month follow-up point, and the data suggests the therapy is still efficacious with no long-term complications detected. Nine months on from treatment the first sickle cell disease patient is also displaying promising results, free of any sickle cell-related adverse events.
“In my 25 years of caring for children and young adults facing both sickle cell disease and beta thalassemia, I have seen how these diseases can adversely affect patients’ lives in very significant ways,” says Haydar Frangoul, from the Sarah Cannon Research Institute. “I am encouraged by the preliminary results, which demonstrate, in essence, a functional cure for patients with beta thalassemia and sickle cell disease.”
Genetic diseases shorten lives and represent significant drains of finances for many families. The promise of a cure has long been too much to hope for but we are likely to see sickle cell anaemia, thalassemia, cystic fibrosis and muscular dystrophy eradicated in our lifetimes.Click HERE to subscribe to Fuller Treacy Money Back to top